Sandbox:Ezici: Difference between revisions
Jump to navigation
Jump to search
Adnan Ezici (talk | contribs) No edit summary |
Adnan Ezici (talk | contribs) Undo revision 1698426 by Adnan Ezici (talk) Tag: Undo |
||
Line 4: | Line 4: | ||
==Historical Perspective== | ==Historical Perspective== | ||
Hydrops fetalis was first discovered by Dr. John William Ballantyne, a Scottish physician and | Hydrops fetalis was first discovered by Dr. John William Ballantyne, a Scottish physician and obstetrician, in 1892. | ||
==Classification== | ==Classification== | ||
Hydrops Fetalis may be classified into two groups based on the presence or absence of | Hydrops Fetalis may be classified into two groups based on the presence or absence of rhesus iso-immunization: | ||
*''' | *'''Immune Hydrops Fetalis''' | ||
*'''Non-Immune Hydrops Fetalis (NIHF)''' | *'''Non-Immune Hydrops Fetalis (NIHF)''' | ||
==Pathophysiology== | ==Pathophysiology== | ||
*It is thought that hydrops fetalis is caused by conditions with either increased rate of fluid transudation from the | *It is thought that hydrops fetalis is caused by conditions with either increased rate of fluid transudation from the vascular compartment or decreased lymphatic return to the circulation. | ||
*This is shown to be originated from developmental defects in | *This is shown to be originated from developmental defects in microcirculation and lymphatic system, respectively.<ref name="pmid33085361">{{cite journal |vauthors=Vanaparthy R, Mahdy H |title= |journal= |volume= |issue= |pages= |date= |pmid=33085361 |doi= |url=}}</ref> | ||
*The potential causes may be | *The potential causes may be immune or non-immune, and they often result in anemia and further hypoxia. | ||
*The sympathetic system becomes activated due to hypoxia, and it causes blood redistribution with decreased blood flow to the liver and kidneys. | *The sympathetic system becomes activated due to hypoxia, and it causes blood redistribution with decreased blood flow to the liver and kidneys. | ||
*Decreased blood flow to the liver and kidneys, results in decreased albumin, increased ADH, and increased activity of RAAS. | *Decreased blood flow to the liver and kidneys, results in decreased albumin, increased ADH, and increased activity of RAAS. | ||
*Following these changes, the central venous pressure increases, which further results in decreased lymphatic return. | *Following these changes, the central venous pressure increases, which further results in decreased lymphatic return. | ||
*As a result, hydrops fetalis (the accumulation of fluid, or edema, in at least two fetal compartments) occurs. | *As a result, hydrops fetalis (the accumulation of fluid, or edema, in at least two fetal compartments)<ref name="pmid30124157">{{cite journal| author=Kontomanolis EN, Fasoulakis Z| title=Hydrops Fetalis and THE Parvovirus B-19. | journal=Curr Pediatr Rev | year= 2018 | volume= 14 | issue= 4 | pages= 239-252 | pmid=30124157 | doi=10.2174/1573396314666180820154340 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30124157 }} </ref> occurs. | ||
*The pathophysiology of non-immune causes also depend on the underlying conditions, include: | *The pathophysiology of non-immune causes also depend on the underlying conditions, include: | ||
**Decreased ventricular filling during diastole (i.e. tachyarrhythmias) | **Decreased ventricular filling during diastole (i.e. tachyarrhythmias) | ||
**Increased central venous pressure due to the increased right heart pressure (i.e. cardiac tumors and subendocardial fibroelastosis) | **Increased central venous pressure due to the increased right heart pressure (i.e. cardiac tumors and subendocardial fibroelastosis) | ||
**Obstruction of lymphatic drainage due to a mass (i.e. cystic hygroma) | **Obstruction of lymphatic drainage due to a mass (i.e. cystic hygroma) | ||
==Causes== | ==Causes== | ||
Hydrops Fetalis is caused by either immune or non-immune conditions. | Hydrops Fetalis is caused by either immune or non-immune conditions. | ||
*'''Immune hydrops fetalis''' | *'''Immune hydrops fetalis''' | ||
**Antibodies may occur due to the exposure of non-self RBC antigens during the previous pregnancy or transfusion. | **Antibodies may occur due to the exposure of non-self RBC antigens during the previous pregnancy or transfusion. | ||
**In the next pregnancy, these antibodies may attack the fetal erythrocytes if the fetus has that antigen. | **In the next pregnancy, these antibodies may attack the fetal erythrocytes if the fetus has that antigen. | ||
**Following the red blood cell destruction, hemolytic disease of the fetus and newborn (HDFN) may occur with a wide range of clinical outcome from only mild anemia to high output heart failure and hydrops fetalis. | **Following the red blood cell destruction, hemolytic disease of the fetus and newborn (HDFN) may occur with a wide range of clinical outcome from only mild anemia to high output heart failure and hydrops fetalis.<ref name="pmid16041667">{{cite journal |vauthors=Moise KJ |title=Red blood cell alloimmunization in pregnancy |journal=Semin Hematol |volume=42 |issue=3 |pages=169–78 |date=July 2005 |pmid=16041667 |doi=10.1053/j.seminhematol.2005.04.007 |url=}}</ref> | ||
***Rh disease is the major cause for immune-mediated hydrops fetalis; however, owing to preventative methods developed in the 1970s, the incidence of Rh disease has markedly declined. | ***Rh disease is the major cause for immune-mediated hydrops fetalis; however, owing to preventative methods developed in the 1970s, the incidence of Rh disease has markedly declined. | ||
***Rh disease can be prevented by administration of anti-D IgG (Rho (D) Immune Globulin) injections to RhD-negative mothers during pregnancy and/or within 72 hours of the delivery. | ***Rh disease can be prevented by administration of anti-D IgG (Rho (D) Immune Globulin) injections to RhD-negative mothers during pregnancy and/or within 72 hours of the delivery. | ||
*'''Non-immune hydrops fetalis (NIHF)''' | *'''Non-immune hydrops fetalis (NIHF)''' | ||
**Currently, with the decreased prevelance of Rh disease, non-immune causes are responsible for up to 90% of cases. | **Currently, with the decreased prevelance of Rh disease, non-immune causes are responsible for up to 90% of cases. | ||
**The most common causes of non-immune hydrops fetalis are hematologic diseases, and chromosomal abnormalities, followed by lymphatic anomalies, and cardiovascular diseases. Causes of NIHF include: | **The most common causes of non-immune hydrops fetalis are hematologic diseases, and chromosomal abnormalities, followed by lymphatic anomalies, and cardiovascular diseases. Causes of NIHF include:<ref name="pmid25712632">{{cite journal |vauthors=Bellini C, Donarini G, Paladini D, Calevo MG, Bellini T, Ramenghi LA, Hennekam RC |title=Etiology of non-immune hydrops fetalis: An update |journal=Am J Med Genet A |volume=167A |issue=5 |pages=1082–8 |date=May 2015 |pmid=25712632 |doi=10.1002/ajmg.a.36988 |url=}}</ref><ref name="pmid22302731">{{cite journal |vauthors=Bellini C, Hennekam RC |title=Non-immune hydrops fetalis: a short review of etiology and pathophysiology |journal=Am J Med Genet A |volume=158A |issue=3 |pages=597–605 |date=March 2012 |pmid=22302731 |doi=10.1002/ajmg.a.34438 |url=}}</ref> | ||
***Structural cardiac malformations (especially hypoplastic left heart, endocardial cushion defect) | ***Structural cardiac malformations (especially hypoplastic left heart, endocardial cushion defect) | ||
***Arrhythmias | ***Arrhythmias | ||
Line 65: | Line 64: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
*In developed countries, the incidence of non-immune hydrops fetalis (NIHF) is 25-79 per 100.000 live born infants worldwide. | *In developed countries, the incidence of non-immune hydrops fetalis (NIHF) is 25-79 per 100.000 live born infants worldwide.<ref name="MengLi2019">{{cite journal|last1=Meng|first1=Dahua|last2=Li|first2=Qifei|last3=Hu|first3=Xuehua|last4=Wang|first4=Lifang|last5=Tan|first5=Shuyin|last6=Su|first6=Jiasun|last7=Zhang|first7=Yue|last8=Sun|first8=Weijia|last9=Chen|first9=Biyan|last10=He|first10=Sheng|last11=Lin|first11=Fei|last12=Xie|first12=Bobo|last13=Chen|first13=Shaoke|last14=Agrawal|first14=Pankaj B.|last15=Luo|first15=Shiyu|last16=Fu|first16=Chunyun|title=Etiology and Outcome of non-immune Hydrops Fetalis in Southern China: report of 1004 cases|journal=Scientific Reports|volume=9|issue=1|year=2019|issn=2045-2322|doi=10.1038/s41598-019-47050-6}}</ref><ref name="pmid28533037">{{cite journal |vauthors=Steurer MA, Peyvandi S, Baer RJ, MacKenzie T, Li BC, Norton ME, Jelliffe-Pawlowski LL, Moon-Grady AJ |title=Epidemiology of Live Born Infants with Nonimmune Hydrops Fetalis-Insights from a Population-Based Dataset |journal=J Pediatr |volume=187 |issue= |pages=182–188.e3 |date=August 2017 |pmid=28533037 |doi=10.1016/j.jpeds.2017.04.025 |url=}}</ref> | ||
*The median gestational age (GA) at diagnosis of NIHF is 23 weeks. | *The median gestational age (GA) at diagnosis of NIHF is 23 weeks. | ||
*Gestational age is predictive of mortality, as preterm infants with this condition are more likely to die. | *Gestational age is predictive of mortality, as preterm infants with this condition are more likely to die. | ||
*The case-fatality rate of NIHF is ranged from 43.2% to 78.2%. | *The case-fatality rate of NIHF is ranged from 43.2% to 78.2%.<ref name="pmid26712114">{{cite journal |vauthors=Ota S, Sahara J, Mabuchi A, Yamamoto R, Ishii K, Mitsuda N |title=Perinatal and one-year outcomes of non-immune hydrops fetalis by etiology and age at diagnosis |journal=J Obstet Gynaecol Res |volume=42 |issue=4 |pages=385–91 |date=April 2016 |pmid=26712114 |doi=10.1111/jog.12922 |url=}}</ref> <ref name="TurgalOzyuncu2015">{{cite journal|last1=Turgal|first1=Mert|last2=Ozyuncu|first2=Ozgur|last3=Boyraz|first3=Gokhan|last4=Yazicioglu|first4=Aslihan|last5=Sinan Beksac|first5=Mehmet|title=Non-immune hydrops fetalis as a diagnostic and survival problems: what do we tell the parents?|journal=Journal of Perinatal Medicine|volume=43|issue=3|year=2015|issn=1619-3997|doi=10.1515/jpm-2014-0094}}</ref> | ||
==Risk Factors== | ==Risk Factors== | ||
Line 75: | Line 74: | ||
==References== | ==References== | ||
<br /> | <br /> | ||
Revision as of 10:33, 24 April 2021
Hydrops Fetalis
Overview
Historical Perspective
Hydrops fetalis was first discovered by Dr. John William Ballantyne, a Scottish physician and obstetrician, in 1892.
Classification
Hydrops Fetalis may be classified into two groups based on the presence or absence of rhesus iso-immunization:
- Immune Hydrops Fetalis
- Non-Immune Hydrops Fetalis (NIHF)
Pathophysiology
- It is thought that hydrops fetalis is caused by conditions with either increased rate of fluid transudation from the vascular compartment or decreased lymphatic return to the circulation.
- This is shown to be originated from developmental defects in microcirculation and lymphatic system, respectively.[1]
- The potential causes may be immune or non-immune, and they often result in anemia and further hypoxia.
- The sympathetic system becomes activated due to hypoxia, and it causes blood redistribution with decreased blood flow to the liver and kidneys.
- Decreased blood flow to the liver and kidneys, results in decreased albumin, increased ADH, and increased activity of RAAS.
- Following these changes, the central venous pressure increases, which further results in decreased lymphatic return.
- As a result, hydrops fetalis (the accumulation of fluid, or edema, in at least two fetal compartments)[2] occurs.
- The pathophysiology of non-immune causes also depend on the underlying conditions, include:
- Decreased ventricular filling during diastole (i.e. tachyarrhythmias)
- Increased central venous pressure due to the increased right heart pressure (i.e. cardiac tumors and subendocardial fibroelastosis)
- Obstruction of lymphatic drainage due to a mass (i.e. cystic hygroma)
Causes
Hydrops Fetalis is caused by either immune or non-immune conditions.
- Immune hydrops fetalis
- Antibodies may occur due to the exposure of non-self RBC antigens during the previous pregnancy or transfusion.
- In the next pregnancy, these antibodies may attack the fetal erythrocytes if the fetus has that antigen.
- Following the red blood cell destruction, hemolytic disease of the fetus and newborn (HDFN) may occur with a wide range of clinical outcome from only mild anemia to high output heart failure and hydrops fetalis.[3]
- Rh disease is the major cause for immune-mediated hydrops fetalis; however, owing to preventative methods developed in the 1970s, the incidence of Rh disease has markedly declined.
- Rh disease can be prevented by administration of anti-D IgG (Rho (D) Immune Globulin) injections to RhD-negative mothers during pregnancy and/or within 72 hours of the delivery.
- Non-immune hydrops fetalis (NIHF)
- Currently, with the decreased prevelance of Rh disease, non-immune causes are responsible for up to 90% of cases.
- The most common causes of non-immune hydrops fetalis are hematologic diseases, and chromosomal abnormalities, followed by lymphatic anomalies, and cardiovascular diseases. Causes of NIHF include:[4][5]
- Structural cardiac malformations (especially hypoplastic left heart, endocardial cushion defect)
- Arrhythmias
- Congenital lymphatic dysplasia
- Chromosomal abnormalities (Turner Syndrome, trisomy 13, trisomy 18, trisomy 21)
- Alpha-thalassemia
- Fetomaternal transfusion
- Infections (Parvo-B19, CMV, Adenovirus, Enterovirus)
- Twin to twin transfusion syndrome (both donor and recipient fetus)
- Congenital cystic adenomatoid malformation
- Diaphragmatic hernia
- Extrapulmonary sequestration
- Hydrothorax
- Chylothorax
- Noonan Syndrome
- Urethral Obstruction
- Prune belly syndrome
- Lysosomal storage disease
- Vascular tumors
- Teratoma
- Leukemia
- Hepatic tumors
- Neuroblastoma
- Meconium peritonitis
- Gastrointestinal obstructions
Epidemiology and Demographics
- In developed countries, the incidence of non-immune hydrops fetalis (NIHF) is 25-79 per 100.000 live born infants worldwide.[6][7]
- The median gestational age (GA) at diagnosis of NIHF is 23 weeks.
- Gestational age is predictive of mortality, as preterm infants with this condition are more likely to die.
- The case-fatality rate of NIHF is ranged from 43.2% to 78.2%.[8] [9]
Risk Factors
References
- ↑ Vanaparthy R, Mahdy H. PMID 33085361 Check
|pmid=
value (help). Missing or empty|title=
(help) - ↑ Kontomanolis EN, Fasoulakis Z (2018). "Hydrops Fetalis and THE Parvovirus B-19". Curr Pediatr Rev. 14 (4): 239–252. doi:10.2174/1573396314666180820154340. PMID 30124157.
- ↑ Moise KJ (July 2005). "Red blood cell alloimmunization in pregnancy". Semin Hematol. 42 (3): 169–78. doi:10.1053/j.seminhematol.2005.04.007. PMID 16041667.
- ↑ Bellini C, Donarini G, Paladini D, Calevo MG, Bellini T, Ramenghi LA, Hennekam RC (May 2015). "Etiology of non-immune hydrops fetalis: An update". Am J Med Genet A. 167A (5): 1082–8. doi:10.1002/ajmg.a.36988. PMID 25712632.
- ↑ Bellini C, Hennekam RC (March 2012). "Non-immune hydrops fetalis: a short review of etiology and pathophysiology". Am J Med Genet A. 158A (3): 597–605. doi:10.1002/ajmg.a.34438. PMID 22302731.
- ↑ Meng, Dahua; Li, Qifei; Hu, Xuehua; Wang, Lifang; Tan, Shuyin; Su, Jiasun; Zhang, Yue; Sun, Weijia; Chen, Biyan; He, Sheng; Lin, Fei; Xie, Bobo; Chen, Shaoke; Agrawal, Pankaj B.; Luo, Shiyu; Fu, Chunyun (2019). "Etiology and Outcome of non-immune Hydrops Fetalis in Southern China: report of 1004 cases". Scientific Reports. 9 (1). doi:10.1038/s41598-019-47050-6. ISSN 2045-2322.
- ↑ Steurer MA, Peyvandi S, Baer RJ, MacKenzie T, Li BC, Norton ME, Jelliffe-Pawlowski LL, Moon-Grady AJ (August 2017). "Epidemiology of Live Born Infants with Nonimmune Hydrops Fetalis-Insights from a Population-Based Dataset". J Pediatr. 187: 182–188.e3. doi:10.1016/j.jpeds.2017.04.025. PMID 28533037.
- ↑ Ota S, Sahara J, Mabuchi A, Yamamoto R, Ishii K, Mitsuda N (April 2016). "Perinatal and one-year outcomes of non-immune hydrops fetalis by etiology and age at diagnosis". J Obstet Gynaecol Res. 42 (4): 385–91. doi:10.1111/jog.12922. PMID 26712114.
- ↑ Turgal, Mert; Ozyuncu, Ozgur; Boyraz, Gokhan; Yazicioglu, Aslihan; Sinan Beksac, Mehmet (2015). "Non-immune hydrops fetalis as a diagnostic and survival problems: what do we tell the parents?". Journal of Perinatal Medicine. 43 (3). doi:10.1515/jpm-2014-0094. ISSN 1619-3997.